drugset / Trial / NCT05360615

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

NCT05360615

Phase 1 Active not recruiting 147 enrolled Chulalongkorn University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Timeline

Start
2022-07-01
Primary completion
2024-06-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg

Indications

No indication recorded.